Market – Page 2

PTC’s Novartis-partnered Huntington’s drug disappoints in mid-stage data reveal

1 month ago talkbio0Tagged factor IX, Huntington 's disease, Market, PTC518

PTC518, factor IX, Huntington ‘s disease, Market

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

1 month ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Mercks Gardasil sales sink further amid China market pressure

1 month ago talkbio0Tagged China, Gardasil, Gardasil sales, Growth, Market, Pressure- physical agent

Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

2 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2 months ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

2 months ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

2 months ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Pharma stocks swerve as Trump hits pause on most tariffs

2 months ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses

Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

2 months ago talkbio0Tagged AstraZeneca, Biotechnology, Chaudhuri, commercial, gene therapy, Kresladi, launch, Market, Mozafancogene Autotemcel, Rocket, Sarbani

Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.